On Wednesday, JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO)’s shares inclined 1.02% to $8.92.
JA Solar Holdings Co., Ltd. (ADR) (JASO)’s board intends to form a special committee comprising of independent directors to consider the proposal.
CEO Baofang Jin said he would pay $9.69 per U.S. share for each share he doesn’t presently own, a 20% premium on Thursday’s closing price. The CEO together with his company, Jinglong Group, already own 15% of JA Solar.
JA Solar Holdings Co., Ltd., together with its auxiliaries, designs, develops, manufactures, and sells photovoltaic solar cells and solar power products based on crystalline silicon technologies. The company’s principal products comprise monocrystalline and multicrystalline solar cells and modules. It also provides monocrystalline and multicrystalline silicon wafers; solar product processing services; and engineering, procurement, and construction services to independent power project developers and public utility companies.
Crocs, Inc. (NASDAQ:CROX)’s shares gained 2.65% to $15.47.
Crocs, Inc. (CROX) declared that Carrie Teffner, the executive vice president and chief financial officer for PetSmart, Inc. (PETM), has been designated to its board of directors. Crocs also declared that current director Peter Jacobi is voluntarily retiring from his position. Both changes were effected on June 9, 2015.
Teffner brings more than 27 years of consumer goods and retail leadership experience to Crocs’ board, most as the executive vice president and chief financial officer for PetSmart. After joining PetSmart in 2013, Teffner supported the company’s continued growth and evolution, counting its recent sale to a consortium led by London-based BC Partners for $8.7 billion. Prior to her position at PetSmart, Teffner served in the chief financial officer role for Weber-Stephen Products, a manufacturer of grills and grill accessories, and for Timberland, a footwear manufacturer and retailer. Teffner spent the first 21 years of her career in various business and leadership roles for Sara Lee Corporation.
Crocs, Inc. designs, develops, manufactures, markets, and distributes casual lifestyle footwear, apparel, and accessories for men, women, and children worldwide. The company designs and sells a range of footwear and accessories that utilize its proprietary closed cell-resin, called Croslite. Its footwear products comprise sandals, sneakers, mules, and flats and boots. Crocs, Inc. offers its accessories products with colorful snap-on charms under the Jibbitz brand name. The company sells its products through retailers and distributors, in addition to directly to consumers through its company-operated retail stores, outlets, Web stores, and kiosks in about 90 countries.
At the end of Wednesday’s trade, Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL)‘s shares surged 0.41% to $2.45.
Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) declared the formation of a 50/50 joint venture with Stolt-Nielsen Limited to pursue opportunities in small-scale LNG production and distribution. Stolt-Nielsen has also made a planned investment in Golar through open market purchases, representing an ownership stake of about 2.3%.
The joint venture between Golar and Stolt-Nielsen will draw upon the logistics and small-scale LNG assets controlled by Stolt-Nielsen and the ocean-based LNG midstream assets controlled by Golar to provide a fully integrated LNG logistics service to consumers of natural gas.
Gol Linhas Aéreas Inteligentes S.A. provides regular and non-regular air transportation services for passengers, cargoes, and mailbags in Brazil and internationally. The company operates in two segments, Flight Transportation and Smiles Loyalty Program. As of December 31, 2014, it operated a fleet of 144 aircraft, which comprised of 96 aircraft under operating leases, 45 aircraft under finance leases, and 3 aircraft owned by the company.
Depomed Inc (NASDAQ:DEPO), ended its Wednesday’s trading session with -1.35% loss, and closed at $21.19.
Depomed Inc (DEPO) declared it has reached a settlement agreement in its ongoing patent litigation related to an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Depomed’s Zipsor® (diclofenac liquid filled capsules) 25mg tablets. The settlement permits defendant Watson Laboratories Inc. to start selling generic Zipsor on March 24, 2022, or earlier under certain circumstances. The settlement concludes all ongoing ANDA litigation related to Zipsor.
The settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
